William Blair Issues Pessimistic Outlook for TARS Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at William Blair dropped their Q1 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a note issued to investors on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn ($0.82) per share for the quarter, down from their prior forecast of ($0.72). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.82) EPS, Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($1.70) EPS and FY2025 earnings at ($1.70) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday. The Goldman Sachs Group raised their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Guggenheim reaffirmed a “buy” rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday. Oppenheimer increased their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Finally, Barclays decreased their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $61.33.

Tarsus Pharmaceuticals Stock Performance

Tarsus Pharmaceuticals stock opened at $43.55 on Friday. The stock’s 50 day moving average is $51.14 and its 200 day moving average is $43.00. The company has a market capitalization of $1.66 billion, a P/E ratio of -11.43 and a beta of 1.01. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TARS. Crowley Wealth Management Inc. purchased a new stake in Tarsus Pharmaceuticals in the fourth quarter worth approximately $25,000. GF Fund Management CO. LTD. purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter worth $44,000. R Squared Ltd bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth $53,000. FMR LLC lifted its holdings in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after acquiring an additional 3,537 shares during the period. Finally, Quarry LP purchased a new position in Tarsus Pharmaceuticals in the fourth quarter worth about $166,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.